Ferchen, Kyle https://orcid.org/0000-0002-3470-3623
Zhang, Xuan https://orcid.org/0000-0001-7966-8748
Thakkar, Kairavee https://orcid.org/0000-0003-1397-486X
Li, Guangyuan https://orcid.org/0000-0002-0628-2454
Bernardicius, David
Sen, Sidharth
Rawat, Priyanka https://orcid.org/0000-0003-4248-347X
Olsson, Andre
Bennett, Sierra N.
Potter, Crystal
Finkelman, Fred D.
Croteau, Josh https://orcid.org/0000-0002-8142-0482
Morris, Samantha https://orcid.org/0000-0001-8561-4340
Singh, Harinder https://orcid.org/0000-0002-6330-8526
Salomonis, Nathan https://orcid.org/0000-0001-9689-2469
Grimes, H. Leighton https://orcid.org/0000-0001-8162-6758
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (RC2DK122376)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL122661)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32CA117846)
Article History
Received: 7 March 2025
Accepted: 11 September 2025
First Online: 22 October 2025
Competing interests
: J.C. declares that they are an employee and stakeholder of BioLegend (a part of the Revvity group of companies). S.M. is a co-founder of CapyBio Inc. The other authors declare no competing interests.